[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Witteveen PO, van der Velden J, Vergote I, Guerra C, Scarabeli C, Coens C, Demonty G, Reed N: Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer--Gynaecological Cancer Group). Ann Oncol; 2009 Sep;20(9):1511-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer--Gynaecological Cancer Group).
  • BACKGROUND: No standard treatment options are available for patients with advanced, recurrent or metastatic vulvar carcinoma not amenable for locoregional treatment.
  • PATIENTS AND METHODS: In this phase II study, patients with advanced vulvar cancer received paclitaxel (Taxol) every 3 weeks for up to 10 cycles.
  • SAFETY: Grade 3 and 4 neutropenia was seen in eight patients (8/29 = 27.6%), which in one patient resulted in neutropenic fever and treatment-related death.
  • Further treatment-related grade 3/4 toxicity includes fatigue in three patients (10.3%) and neuropathy in one patient (3.4%).
  • CONCLUSION: Paclitaxel shows moderate activity for local control in advanced vulvar cancer.

  • Genetic Alliance. consumer health - Vulvar cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2001;60(1):66-71 [11150911.001]
  • [Cites] Gynecol Oncol. 2007 May;105(2):299-303 [17303230.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3113-9 [15284262.001]
  • [Cites] Gynecol Oncol. 1979 Jun;7(3):345-8 [87359.001]
  • [Cites] Cancer Treat Rep. 1980 Apr-May;64(4-5):639-42 [6159078.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Am J Obstet Gynecol. 1982 Jun 1;143(3):340-51 [7081350.001]
  • [Cites] Gynecol Oncol. 1986 Mar;23(3):358-63 [3754234.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Am J Clin Oncol. 1989 Apr;12(2):142-4 [2705404.001]
  • [Cites] Gynecol Oncol. 1990 Mar;36(3):423-7 [1690680.001]
  • [Cites] Gynecol Oncol. 1990 Jun;37(3):359-62 [1693584.001]
  • [Cites] Gynecol Oncol. 1993 Jul;50(1):49-53 [7688709.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):34-7 [7557612.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):792-5 [8622025.001]
  • [Cites] Cancer. 1996 Apr 15;77(8):1472-8 [8608531.001]
  • [Cites] Gynecol Oncol. 1996 Sep;62(3):379-83 [8812536.001]
  • [Cites] Anticancer Drugs. 1997 Aug;8(7):657-61 [9311440.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):79-85 [9747823.001]
  • [Cites] Curr Opin Oncol. 2005 May;17(3):218-24 [15818164.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):53-7 [16257042.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Mar;61(3):222-9 [17092739.001]
  • [Cites] Gynecol Oncol. 2001 Jun;81(3):348-54 [11371121.001]
  • (PMID = 19487487.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 3U10 CA11488-31; United States / NCI NIH HHS / CA / 5U10 CA011488-38
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2731017
  •  go-up   go-down


2. Beleznay KM, Levesque MA, Gill S: Response to 5-fluorouracil in metastatic extramammary Paget disease of the scrotum presenting as pancytopenia and back pain. Curr Oncol; 2009 Sep;16(5):81-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to 5-fluorouracil in metastatic extramammary Paget disease of the scrotum presenting as pancytopenia and back pain.
  • Extramammary Paget disease is a rare intraepithelial neoplasm of the vulvar, penoscrotal, or perianal skin.
  • No effective therapies for metastatic disease have been reported, and prognosis for metastatic disease is poor.Here, we report the case of an Asian man who was initially diagnosed with extramammary Paget disease of the scrotum.
  • The patient was treated with 5-fluorouracil-based therapy in addition to palliative radiotherapy to selected spine levels.
  • A promising palliative response was demonstrated following 5-fluorouracil chemotherapy.A review of the literature on the pathogenesis, diagnosis, treatment options, and outcomes for metastatic extramammary Paget disease is presented.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatol Surg. 2004 Feb;30(2 Pt 2):341-4 [14871231.001]
  • [Cites] J Am Acad Dermatol. 1985 Dec;13(6):1009-14 [3001158.001]
  • [Cites] J Clin Pathol. 2000 Oct;53(10):742-9 [11064666.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2007 May;21(5):581-90 [17447970.001]
  • [Cites] J Dermatol. 2005 Aug;32(8):632-7 [16334862.001]
  • [Cites] J Am Acad Dermatol. 2004 Nov;51(5):767-73 [15523356.001]
  • [Cites] J Dermatol. 1999 May;26(5):311-6 [10380432.001]
  • [Cites] Gynecol Oncol. 1997 Jul;66(1):146-50 [9234936.001]
  • [Cites] Am J Clin Pathol. 1997 Jul;108(1):6-12 [9208972.001]
  • [Cites] J Dermatol. 1996 May;23(5):320-4 [8675821.001]
  • [Cites] Am J Dermatopathol. 1992 Oct;14(5):402-7 [1384380.001]
  • [Cites] Cancer. 1992 Aug 1;70(3):704-8 [1320453.001]
  • [Cites] Histopathology. 1991 Apr;18(4):355-60 [1649114.001]
  • [Cites] J Surg Oncol. 1988 May;38(1):38-44 [2836660.001]
  • [Cites] J Dermatol. 2002 Jan;29(1):33-7 [11837572.001]
  • (PMID = 19862365.001).
  • [ISSN] 1718-7729
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2768510
  • [Keywords] NOTNLM ; 5-fluorouracil / Paget disease / extramammary / metastatic
  •  go-up   go-down


3. Gadducci A, Cionini L, Romanini A, Fanucchi A, Genazzani AR: Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hematol; 2006 Dec;60(3):227-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer.
  • During the last decades there has been a continuing evolution in the surgical approach of squamous cell carcinoma of the vulva that has been traditionally treated with radical vulvectomy and bilateral inguinal-femoral lymphadenectomy.
  • Patients with T1 tumour are usually treated with radical local excision, if the lesion is unifocal and the remainder of the vulva is normal.
  • Modifications of the surgical technique of deep femoral lymphadenectomy and the mapping of sentinel node can offer new interesting therapeutic perspectives.
  • Locally advanced squamous cell carcinoma of the vulva has been long surgically treated with en-block radical vulvectomy and bilateral inguinal-femoral lymphadenectomy plus partial resection of urethra, vagina or anum, or by exenteration, with severe postsurgical complications, poor quality of life, and unsatisfactory survival rates.
  • 5-Fluorouracil [5-FU] or 5-FU- and cisplatin-based chemotherapy concurrent with irradiation followed by tailored surgery represents an attractive therapeutic option for advanced disease, planned to avoid such ultra-radical surgical procedures and, hopefully, to improve patient outcome.
  • Chemotherapy has also been used in neoadjuvant setting, with contrasting and generally unsatisfactory results, and in palliative treatment of patients with distant metastases.
  • Surgery is the primary treatment also for vulvar malignancies other than squamous cell carcinoma, whereas the clinical usefulness of adjuvant irradiation or chemotherapy is still to be defined.
  • Primary chemoradiation can be also used for advanced carcinoma of the Bartholin gland or for advanced adenocarcinoma associated with extramammary Paget's disease.
  • The drugs used for chemotherapy of metastatic melanomas or sarcomas of the vulva are the same employed for the melanomas or sarcomas developed in other sites.
  • [MeSH-major] Vulvar Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Neoplasm Metastasis. Recurrence

  • Genetic Alliance. consumer health - Vulvar cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16945551.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 167
  •  go-up   go-down


Advertisement
4. van Rijswijk RE, Vermorken JB: Drug therapy for gynaecological cancer in older women. Drugs Aging; 2000 Jul;17(1):13-32
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug therapy for gynaecological cancer in older women.
  • Differences in biological behaviour, stage of the disease at presentation, and reluctance to undergo aggressive treatment with its associated morbidity are among the factors thought to be responsible for this difference in outcomes.
  • However, investigations also indicate that elderly patients may receive less surgical and chemotherapeutic treatment without obvious clinical rationale.
  • This overview is aimed at providing a guideline of chemotherapy appropriate for patients with epithelial ovarian, uterine (corpus and cervix), and vulvar cancer, aged 70 to 75 years and over.
  • Platinum-based chemotherapy is the cornerstone of drug treatment in patients with ovarian cancer.
  • Patients aged between 70 and 75 years with a good performance status can be treated with cisplatin- or carboplatin-based chemotherapy.
  • For patients with early recurrence there is no standard treatment, but several cytostatic and hormonal agents can be used with palliative intent.
  • In metastatic endometrial cancer, hormonal therapy is the first choice in tumours expressing a progesterone receptor.
  • Poorly differentiated tumours infrequently respond to endocrine therapy.
  • In this situation, and for patients with tumours that have become resistant to hormonal manipulation, platinum-based chemotherapy may be used.
  • The usefulness of chemotherapy in elderly patients with cervical cancer is limited.
  • In case of recurrent or metastatic disease, the use of single agent (low-dose) cisplatin should be balanced against best supportive care.
  • Although overall chemoradiation seems superior than radiotherapy alone in patients with locally advanced cervical cancer, the feasibility of this approach in elderly patients needs further investigation.
  • Chemoradiation might also be considered in patients with locally advanced vulvar cancer.
  • However, treatment-related morbidity can be considerable and randomised studies are lacking to prove a survival benefit.
  • Our understanding of the tolerance and effectiveness of chemotherapy in elderly patients is still incomplete due to a paucity of trials that specifically focus on this subset of patients.
  • However, there appears no argument to withhold chemotherapy based purely on age.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Genital Neoplasms, Female / drug therapy
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Endometrial Neoplasms / drug therapy. Female. Humans. Neoplasm Recurrence, Local / drug therapy. Neoplasms, Glandular and Epithelial / drug therapy. Ovarian Neoplasms / drug therapy. Uterine Cervical Neoplasms / drug therapy. Vulvar Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):13-7 [8995541.001]
  • [Cites] Semin Oncol. 1995 Feb;22(1 Suppl 1):3-5 [7863350.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2121-5 [7931482.001]
  • [Cites] Eur J Gynaecol Oncol. 1993;14(3):187-91 [8508872.001]
  • [Cites] Gynecol Oncol. 1997 Jul;66(1):20-6 [9234915.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3056-61 [8955650.001]
  • [Cites] Obstet Gynecol. 1997 Nov;90(5):748-54 [9351758.001]
  • [Cites] Gynecol Oncol. 1996 Oct;63(1):89-93 [8898175.001]
  • [Cites] Biomed Pharmacother. 1988;42(8):531-8 [2975957.001]
  • [Cites] Semin Oncol. 1994 Feb;21(1):107-13 [8310301.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2654-66 [7989941.001]
  • [Cites] J Clin Oncol. 1989 Jan;7(1):115-8 [2491882.001]
  • [Cites] Cancer. 1995 Jan 1;75(1):11-7 [7804963.001]
  • [Cites] Gynecol Oncol. 1993 Dec;51(3):397-400 [8112651.001]
  • [Cites] Ann Intern Med. 1979 Nov;91(5):710-7 [496103.001]
  • [Cites] Br J Cancer. 1989 Apr;59(4):650-3 [2713253.001]
  • [Cites] Ann Oncol. 1993 Apr;4(4):289-94 [8518218.001]
  • [Cites] Semin Oncol. 1994 Apr;21(2 Suppl 2):43-54; quiz 55, 58 [8202720.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1957-68 [7691999.001]
  • [Cites] J Clin Oncol. 1993 Dec;11(12):2405-10 [7902426.001]
  • [Cites] J Clin Oncol. 1992 Feb;10(2):243-8 [1732425.001]
  • [Cites] Acta Oncol. 1993;32(6):657-61 [7505091.001]
  • [Cites] Cancer. 1995 Nov 15;76(10 Suppl):2159-70 [8635016.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):278-81 [8751561.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1672-6 [2509641.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2123-34 [9610691.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):270-94 [8001001.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2101-12 [8683243.001]
  • [Cites] Semin Oncol. 1994 Feb;21(1 Suppl 1):17-22 [8153653.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1984 Jun;17(4):285-91 [6235140.001]
  • [Cites] Arch Gerontol Geriatr. 1988 Jun;7(2):119-50 [3046534.001]
  • [Cites] Ann Intern Med. 1994 Jan 15;120(2):104-10 [8256968.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1582-7 [9552069.001]
  • [Cites] Lancet. 1997 Jan 11;349(9045):113-7 [8996432.001]
  • [Cites] J Clin Oncol. 1985 Aug;3(8):1079-85 [3894589.001]
  • [Cites] Ann Oncol. 1992 Mar;3(3):217-22 [1586619.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):693-700 [10442192.001]
  • [Cites] Cancer. 1991 Dec 1;68(11 Suppl):2502-10 [1933793.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2546-51 [8823334.001]
  • [Cites] Obstet Gynecol. 1983 Apr;61(4):413-20 [6828269.001]
  • [Cites] Cancer. 1990 Oct 15;66(8):1697-702 [2119878.001]
  • [Cites] Ann Oncol. 1997 Feb;8(2):181-5 [9093728.001]
  • [Cites] Gynecol Oncol. 1996 Dec;63(3):312-7 [8946864.001]
  • [Cites] Acta Oncol. 1995;34(6):813-20 [7576750.001]
  • [Cites] Cancer. 1995 Nov 15;76(10 Suppl):2044-52 [8634998.001]
  • [Cites] J Natl Cancer Inst. 1993 Oct 6;85(19):1580-4 [8411231.001]
  • [Cites] Am J Obstet Gynecol. 1992 May;166(5):1482-5 [1595803.001]
  • [Cites] Cancer. 1993 Jan 15;71(2 Suppl):638-43 [8420688.001]
  • [Cites] Gynecol Oncol. 1990 Feb;36(2):207-11 [2404837.001]
  • [Cites] Scand Audiol. 1988;17(4):241-7 [3232027.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):172-6 [8996139.001]
  • [Cites] Cancer Res. 1984 Apr;44(4):1693-7 [6367971.001]
  • [Cites] Gynecol Oncol. 1993 Jul;50(1):49-53 [7688709.001]
  • [Cites] Eur J Cancer. 1997 Nov;33(13):2167-70 [9470802.001]
  • [Cites] Cancer. 1993 Jan 15;71(2 Suppl):524-9 [8420672.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):60-3 [8270985.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1339-48 [10334517.001]
  • [Cites] Gynecol Oncol. 1991 Dec;43(3):233-6 [1752493.001]
  • [Cites] Acta Obstet Gynecol Scand. 1984;63(5):441-50 [6238499.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] Curr Opin Oncol. 1996 Sep;8(5):408-14 [8914808.001]
  • [Cites] JAMA. 1998 Apr 15;279(15):1187-93 [9555758.001]
  • [Cites] J Am Geriatr Soc. 1996 Apr;44(4):472-4 [8636602.001]
  • [Cites] Gynecol Oncol. 1989 Jan;32(1):49-54 [2909449.001]
  • [Cites] Ann Oncol. 1996 Feb;7(2):189-95 [8777177.001]
  • [Cites] Cancer Pract. 1996 May-Jun;4(3):130-4 [8826141.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):387-92 [8774643.001]
  • [Cites] Clin Pharmacol Ther. 1997 Mar;61(3):331-9 [9091249.001]
  • [Cites] Gynecol Oncol. 1993 Oct;51(1):109-12 [8244164.001]
  • [Cites] Cancer Treat Rev. 1994 Apr;20(2):191-214 [8156541.001]
  • [Cites] Br J Cancer. 1994 Jan;69(1):191-5 [8286205.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):393-6 [8774644.001]
  • [Cites] Eur J Cancer. 1994;30A(5):697-8 [8080689.001]
  • [Cites] Gynecol Oncol. 1994 Dec;55(3 Pt 2):S143-50 [7835799.001]
  • [Cites] Gynecol Oncol. 1995 Jan;56(1):75-8 [7821851.001]
  • [Cites] Cancer. 1989 Apr 1;63(7):1283-6 [2920357.001]
  • [Cites] Am J Obstet Gynecol. 1986 Mar;154(3):639-47 [3953714.001]
  • [Cites] J Clin Oncol. 1989 Oct;7(10):1462-8 [2674333.001]
  • [Cites] Semin Oncol. 1997 Feb;24(1 Suppl 1):S1-140-S1-50 [9045311.001]
  • [Cites] Lancet. 1998 Nov 14;352(9140):1571-6 [9843101.001]
  • [Cites] Cancer Treat Rep. 1986 Aug;70(8):1019-20 [3731147.001]
  • [Cites] Gynecol Oncol. 1997 Jun;65(3):461-6 [9190976.001]
  • [Cites] Gynecol Oncol. 1993 Jan;48(1):38-49 [8423020.001]
  • [Cites] Semin Oncol. 1993 Feb;20(1):43-9 [8475409.001]
  • [Cites] J Natl Cancer Inst. 1994 Apr 6;86(7):527-37 [8133536.001]
  • [Cites] J Natl Cancer Inst. 1994 Oct 19;86(20):1530-3 [7932808.001]
  • [Cites] Cancer. 1994 Jan 15;73(2):377-83 [8293403.001]
  • [Cites] Gynecol Oncol. 1993 May;49(2):172-6 [8504984.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;26 Suppl:S51-4 [2112053.001]
  • [Cites] Eur J Cancer. 1994;30A(7):911-4 [7946581.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1154-61 [10202166.001]
  • [Cites] Cancer Invest. 1995;13(3):272-5 [7743379.001]
  • [Cites] Cancer. 1996 Apr 15;77(8):1472-8 [8608531.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):4-8 [8995539.001]
  • [Cites] N Engl J Med. 1995 Mar 9;332(10):629-34 [7845426.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1137-43 [10202164.001]
  • [Cites] Gynecol Oncol. 1987 Jun;27(2):208-13 [3570058.001]
  • [Cites] Cancer Treat Rep. 1984 May;68(5):809-11 [6722836.001]
  • [Cites] Gynecol Oncol. 1996 Apr;61(1):22-6 [8626111.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):569-73 [9261526.001]
  • [Cites] Gynecol Oncol. 1999 Apr;73(1):137-9 [10094894.001]
  • [Cites] Clin Pharmacol Ther. 1986 Feb;39(2):136-44 [3943271.001]
  • [Cites] Ann Oncol. 1996 Sep;7(7):677-85 [8905025.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1144-53 [10202165.001]
  • [Cites] Obstet Gynecol. 1997 Oct;90(4 Pt 1):628-31 [9380328.001]
  • [Cites] Am J Clin Oncol. 1996 Aug;19(4):371-4 [8677907.001]
  • [Cites] Cancer. 1993 Jan 15;71(2 Suppl):517-23 [8420671.001]
  • [Cites] Oncol Rep. 1996 Mar;3(2):277-9 [21594359.001]
  • [Cites] Semin Oncol. 1993 Aug;20(4 Suppl 3):1-15 [8102012.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] N Engl J Med. 1996 Jan 4;334(1):1-6 [7494563.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1996 Apr;65(2):201-7 [8730625.001]
  • [Cites] J Clin Oncol. 1994 Sep;12(9):1748-53 [7916038.001]
  • [Cites] Cancer Clin Trials. 1981 Fall;4(3):313-6 [6169465.001]
  • [Cites] J Clin Oncol. 1987 Jan;5(1):141-9 [3543234.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1157-68 [3114434.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):629-38 [10360638.001]
  • [Cites] Anticancer Drugs. 1997 Jun;8(5):432-5 [9215604.001]
  • [Cites] Gynecol Oncol. 1996 Jun;61(3):321-7 [8641609.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):193-8 [8996142.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):51-6 [7557615.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):357-61 [8636744.001]
  • [Cites] J Clin Oncol. 1989 Jan;7(1):108-14 [2642536.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):405-10 [9469322.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1134-40 [9305715.001]
  • [Cites] Gynecol Oncol. 1977 Mar;5(1):52-8 [404216.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):2937-42 [9738561.001]
  • [Cites] J Clin Oncol. 1986 May;4(5):702-9 [3701389.001]
  • [Cites] J Clin Oncol. 1992 Nov;10(11):1748-53 [1357110.001]
  • [Cites] Cancer. 1994 Oct 1;74(7 Suppl):2107-17 [8087778.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):165-71 [8996138.001]
  • [Cites] Cancer. 1993 Jan 15;71(2 Suppl):606-14 [8420683.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):861-3 [8922203.001]
  • [Cites] Gynecol Oncol. 1988 Jul;30(3):347-58 [3134277.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2183-93 [9196130.001]
  • [Cites] Lancet. 1989 Jan 21;1(8630):117-20 [2563046.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 1:87-92 [10219460.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 19;87(8):573-80 [7752255.001]
  • [Cites] Gynecol Oncol. 1990 Jun;37(3):359-62 [1693584.001]
  • [Cites] Eur J Cancer. 1991;27(11):1367-72 [1835850.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):187-92 [8996141.001]
  • [Cites] Am J Med. 1989 Feb;86(2):151-7 [2913782.001]
  • [Cites] CA Cancer J Clin. 1996 Jan-Feb;46(1):5-27 [8548526.001]
  • [Cites] Semin Oncol. 1989 Feb;16(1):66-75 [2645651.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-78-S15-82 [9346228.001]
  • [Cites] Gynecol Oncol. 1990 Dec;39(3):332-6 [2258080.001]
  • [Cites] Lancet. 1997 Aug 23;350(9077):535-40 [9284774.001]
  • [Cites] Int J Gynecol Cancer. 1995 Jul;5(4):301-305 [11578494.001]
  • [Cites] Int J Gynecol Cancer. 1994 Jan;4(1):52-60 [11578385.001]
  • [Cites] BMJ. 1991 Oct 12;303(6807):884-93 [1834291.001]
  • [Cites] Cancer Res. 1984 Nov;44(11):5432-8 [6386150.001]
  • [Cites] Obstet Gynecol. 1990 Apr;75(4):696-700 [2179783.001]
  • [Cites] J Clin Oncol. 1987 Feb;5(2):304-9 [3806171.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):269-71 [2070324.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):389-93 [1999708.001]
  • [Cites] BMJ. 1999 Apr 24;318(7191):1108-11 [10213718.001]
  • [Cites] Gynecol Oncol. 1997 Aug;66(2):258-61 [9264573.001]
  • [Cites] Gynecol Oncol. 1990 Feb;36(2):166-71 [2298404.001]
  • [Cites] Gynecol Oncol. 1989 Feb;32(2):198-202 [2910782.001]
  • [Cites] Cancer. 1997 Oct 1;80(7):1317-22 [9317185.001]
  • [Cites] J Clin Oncol. 1991 Jun;9(6):1071-88 [2033421.001]
  • [Cites] J Psychosom Res. 1992 Sep;36(6):531-41 [1640391.001]
  • [Cites] Gynecol Oncol. 1991 Sep;42(3):197-201 [1955180.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):395-401 [8625250.001]
  • [Cites] Int J Gynecol Cancer. 1993 May;3(3):129-142 [11578333.001]
  • [Cites] Semin Oncol. 1992 Oct;19(5):521-8 [1411650.001]
  • [Cites] Gynecol Oncol. 1993 Apr;49(1):86-91 [8482566.001]
  • [Cites] Br J Cancer. 1992 Apr;65(4):621-3 [1314071.001]
  • [Cites] Ann Oncol. 2001 Jul;12(7):967-74 [11521804.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1552-7 [8622071.001]
  • [Cites] Gynecol Oncol. 1992 Dec;47(3):282-6 [1473738.001]
  • [Cites] Cancer. 1997 Oct 1;80(7):1273-83 [9317180.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Aug 1;26(5):809-16 [8344850.001]
  • [Cites] Gynecol Oncol. 1994 Apr;53(1):33-7 [8175019.001]
  • [Cites] Ann Intern Med. 1990 Dec 1;113(11):834-40 [2146911.001]
  • [Cites] Ann Intern Med. 1989 Aug 15;111(4):273-9 [2569287.001]
  • [Cites] Pharmacotherapy. 1997 Sep-Oct;17(5 Pt 2):96S-104S [9322876.001]
  • (PMID = 10933513.001).
  • [ISSN] 1170-229X
  • [Journal-full-title] Drugs & aging
  • [ISO-abbreviation] Drugs Aging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 203
  •  go-up   go-down


5. Yamamoto R, Sakuragi N, Shirato H, Shimizu M, Fujimoto S: Radiotherapy with concurrent chemotherapy for vulvar adenocarcinoma associated with extramammary Paget's disease. Gynecol Oncol; 2001 Feb;80(2):267-71
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy with concurrent chemotherapy for vulvar adenocarcinoma associated with extramammary Paget's disease.
  • BACKGROUND: There have been no reports of the efficacy of primary radiotherapy with concurrent chemotherapy for vulvar adenocarcinoma associated with extramammary Paget's disease.
  • In this report we discuss the differential diagnosis and efficacy of treatment for this rare tumor.
  • CASE: The patient was diagnosed as having vulvar carcinoma stage IVb.
  • A dose of 40 Gy in 20 fractions was administered to the vulva, including the tumor mass, and the inguinal-femoral lymph nodes with concurrent systemic chemotherapy.
  • CONCLUSION: Within the radiated field, the efficacy was brought about by either radiotherapy only or by radiotherapy together with the sensitizing effects of chemotherapy.
  • As for the chemotherapy itself, it was not effective in this case.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Paget Disease, Extramammary / drug therapy. Paget Disease, Extramammary / radiotherapy. Vulvar Neoplasms / drug therapy. Vulvar Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Diagnosis, Differential. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11161871.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Richard SD, Krivak TC, Beriwal S, Zorn KK: Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):1132-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab.
  • Recurrent vulvar carcinoma with metastasis has few effective treatment options, which are mainly directed toward palliation of symptoms.
  • A 70-year-old woman was originally treated in 1999 for vulvar squamous cell carcinoma (SCC) with radical vulvectomy and bilateral inguinofemoral groin dissection.
  • Although treatment of this area included surgical resection and chemoradiation, she recurred 3 months later.
  • Despite radical surgical resection with an anal perineal resection, she presented 2 months later with widely metastatic disease.
  • She was treated with palliative radiation therapy (RT) and a cetuximab plus cisplatin chemotherapy protocol.
  • Few treatment options exist for recurrent metastatic vulvar carcinoma.
  • The combination of the EGFR antagonist cetuximab with cisplatin has shown modest success in other metastatic SCCs.
  • The partial response experienced in our patient suggests its potential use in women with recurrent or metastatic vulvar carcinoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Vulvar Neoplasms / drug therapy. Vulvar Neoplasms / pathology
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Cetuximab. Female. Humans. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neoplasm Metastasis / radiography. Recurrence. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021214.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; PQX0D8J21J / Cetuximab; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Piura B: Management of primary melanoma of the female urogenital tract. Lancet Oncol; 2008 Oct;9(10):973-81
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They usually affect elderly women and account for less than 10% of all cancer of the urogenital tract in women and less than 10% of all melanoma diagnosed in women.
  • Tumour staging can be challenging; however, the American Joint Committee on Cancer melanoma staging system has been recommended for use in vulvar and vaginal melanoma.
  • Surgery is the treatment of choice; less-extensive surgery can be a sensible approach because satisfactory locoregional control might be obtained from wide local excision and radiotherapy, without the morbidity and disfigurement associated with radical surgery.
  • Complete regional lymphadenectomy does not seem necessary if a sentinel lymph-node biopsy sample is negative; however, this decision should be made with caution.
  • Various chemotherapy and biotherapy (ie, immunotherapy and biological-response modifiers) regimens have been used in advanced or metastatic melanoma.
  • However, the role of chemotherapy for women with urogenital-tract melanoma has not been established, and biotherapy methods presented to date have been anecdotal.
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19071254.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 75
  •  go-up   go-down


8. Khouchani M, Benchakroun N, Tahri A, Tawfiq N, Jouhadi H, Acharki A, Sahraoui S, Belaabidia B, Benider A: [Breast metastasis from vulvar carcinoma: case report and review of literature]. Cancer Radiother; 2008 Mar;12(2):120-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast metastasis from vulvar carcinoma: case report and review of literature].
  • [Transliterated title] Métastase intramammaire d'un cancer vulvaire: à propos d'un cas avec revue de la littérature.
  • The breast metastases resulting of vulvar carcinoma are very rare, and represent exceptionally the first manifestation of the disease.
  • We report the case of a 42 year-old patient who underwent a treatment because of vulvar epidermoid carcinoma, right away metastatic at the level of the inguinal ganglia.
  • The treatment consisted in a total vulvectomy with bilateral ganglial curretage, followed by external radiotherapy about the perineum and the inguinal ganglia.
  • Three months after the end of her treatment, the patient presented with a nodula on the left outer breast with features of malignancy noticed by clinic and mammographic examination.
  • The histologic study of the mammary biopsy showed epidermoid carcinoma of likely metastatic origin.
  • A left Patey has been realized and confirmed the metastatic localization of epidermoid carcinoma with axillary ganglial metastasis (2N+/-7).
  • Besides, this patient presented a right cervical ganglial parcel that the biopsy showed a metastatic localization of a vulvar carcinoma.
  • A palliative chemotherapy type cyclophosphamid, adriblastin, cisplatine (CAP) has been admistrated during three cycles spaced out three weeks.
  • We present this case because its rarety and to show the possibility of metastasis at the level of breast due to vulvar cancer.
  • The clinicians must remember this possible tropism of the vulvar cancer for the breast, not only during the supervision and the complete examination as regards the disease spreading but also when the affection revealed unknown primary tumor.
  • In this stage, the treatment is unfortunately palliative, the survival until a year is not more than 20%.
  • [MeSH-major] Breast Neoplasms / secondary. Carcinoma, Squamous Cell / secondary. Vulvar Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343704.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 31
  •  go-up   go-down


9. Yen TC, Lai CH: Positron emission tomography in gynecologic cancer. Semin Nucl Med; 2006 Jan;36(1):93-104
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography in gynecologic cancer.
  • Most positron emission tomography (PET) imaging studies in gynecologic cancer are performed using (18)F-fluorodeoxyglucose (FDG).
  • It contributes valuable information in primary staging of untreated advanced cervical cancer, in the post-treatment surveillance with unexplained tumor marker (such as squamous cell carcinoma antigen [SCC-Ag]) elevation or suspicious of recurrence, and restaging of potentially curable recurrent cervical cancer.
  • Its value in early-stage resectable cervical cancer is questionable.
  • In ovarian cancer, FDG-PET provides benefits for those with plateaued or increasing abnormal serum CA 125 (>35 U/mL), computed tomography and/or magnetic resonance imaging (CT-MRI) defined localized recurrence feasible for local destructive procedures (such as surgery, radiotherapy, or radiofrequency ablation), and clinically suspected recurrent or persistent cancer for which CT-guide biopsy cannot be performed.
  • The role of FDG-PET in endometrial cancer is relatively less defined because of the lack of data in the literature.
  • In our prospective study, FDG-PET coupled with MRI-CT may facilitate optimal management of endometrial cancer in well-selected cases.
  • The clinical impact was positive in 29 (48.3%) of the 60 scans, 22.2% for primary staging, 73.1% for post-therapy surveillance, and 57.1% after salvage therapy, respectively.
  • Scant studies have been reported in the management of vulvar cancer using FDG-PET.
  • Our preliminary results suggest that FDG-PET is potentially useful in selected gestational trophoblastic neoplasia by providing a precise metastatic mapping of tumor extent up front, monitoring response, and localizing viable tumors after chemotherapy.
  • The evaluation of a diagnostic tool, such as PET, is usually via comparing the diagnostic efficacy (sensitivity, specificity, etc), by using a more sophisticated receiver operating curve method, or the proportion of treatment been modified.
  • [MeSH-major] Fluorodeoxyglucose F18. Genital Neoplasms, Female / radionuclide imaging. Positron-Emission Tomography / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16356798.001).
  • [ISSN] 0001-2998
  • [Journal-full-title] Seminars in nuclear medicine
  • [ISO-abbreviation] Semin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 136
  •  go-up   go-down


10. Kahmann L, Beyer U, Mehlhorn G, Thiel FC, Strnad V, Fasching PA, Lux MP: Mitomycin C in patients with gynecological malignancies. Onkologie; 2010;33(10):547-57
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mitomycin C (MMC) is an effective cytostatic agent used in the treatment of patients with gynecological malignancies and breast carcinoma.
  • This review presents and discusses the current treatment options with MMC in patients with breast, cervical, and vulvar carcinomas, as well as rarer gynecological malignancies.
  • Consequently, also for the next years a MMC-containing chemotherapy continues to be a relevant part of an individualized therapy despite numerous innovative new drugs, especially for the salvage therapy of metastatic breast cancer and the simultaneous radiochemotherapy of other gynecological malignancies.
  • [MeSH-major] Breast Neoplasms / drug therapy. Genital Neoplasms, Female / drug therapy. Mitomycin / therapeutic use. Salvage Therapy / methods
  • [MeSH-minor] Cytostatic Agents / therapeutic use. Female. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • figshare. supplemental materials - Supporting Data and Materials for the article .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 20926904.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Cytostatic Agents; 50SG953SK6 / Mitomycin
  •  go-up   go-down


11. Mottl H, Rob L, Stary J, Kodet R, Drahokoupilova E: Langerhans cell histiocytosis of vulva in adolescent. Int J Gynecol Cancer; 2007 Mar-Apr;17(2):520-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Langerhans cell histiocytosis of vulva in adolescent.
  • Langerhans cell histiocytosis (LCH) affecting child vulva alone is a very rare disease.
  • Only 13 cases of primary vulvar LCH have been previously reported in the medical literature.
  • We describe an additional case in which the LCH was confined to the vulva, with review of the literature.
  • A metastatic work-up did not reveal any evidence of the disease except on the vulva.
  • Treatment was carried out according to LCH II protocol.
  • The patient was diagnosed with a recurrent disorder in the vulva 8 months after the completion of primary chemotherapy.
  • For this reason, she underwent second line treatment with 2-chlorodeoxyadenosine.
  • Eighteen months after the second line chemotherapy, the patient has no signs of a local or systemic recurrence.
  • Primary LCH of vulva is very unusual, but we have to keep in mind this possibility when an adolescent girl presents with an atypical chronic lesion on the vulva.
  • This patient appears to be the first case of adolescent 16.5 year old having a solely cutaneous lesion of the vulva.
  • [MeSH-major] Histiocytosis, Langerhans-Cell / diagnosis. Vulvar Diseases / diagnosis

  • Genetic Alliance. consumer health - Histiocytosis.
  • Genetic Alliance. consumer health - Langerhans cell histiocytosis.
  • MedlinePlus Health Information. consumer health - Vulvar Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17362323.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Matsuo K, Chi DS, Eno ML, Im DD, Rosenshein NB: Vulvar mucinous adenocarcinoma associated with Crohn's disease: report of two cases. Gynecol Obstet Invest; 2009;68(4):276-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vulvar mucinous adenocarcinoma associated with Crohn's disease: report of two cases.
  • However, there have been no previously reported cases documenting vulvar cancer in association with rectovaginal fistula in Crohn's disease.
  • We report 2 cases of vulvar mucinous adenocarcinoma associated with Crohn's disease.
  • Both showed vulvar symptoms after the development of rectovaginal fistula.
  • CASE 1: A 48-year-old woman, with a 30-year history of Crohn's disease including a rectovaginal fistula, developed persistent pyoderma gangrenosum.
  • Further workup revealed metastatic vulvar mucinous adenocarcinoma.
  • CASE 2: A 37-year-old woman with long-standing Crohn's disease including numerous episodes of perianal or rectovaginal fistulas complained of a vulvar mass suspicious for an abscess.
  • CONCLUSION: Vulvar lesions or symptoms in the setting of rectovaginal fistula in Crohn's disease are an important clinical feature and the possible development of vulvar cancer should be considered.
  • [MeSH-major] Adenocarcinoma, Mucinous / etiology. Crohn Disease / complications. Rectovaginal Fistula / complications. Vulvar Neoplasms / etiology
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bevacizumab. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Middle Aged. Organoplatinum Compounds / administration & dosage. Positron-Emission Tomography

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 S. Karger AG, Basel.
  • (PMID = 19828998.001).
  • [ISSN] 1423-002X
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 2S9ZZM9Q9V / Bevacizumab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Bansal N, Cohen CJ, Shah JN, Schiff PB, Herzog TJ, Wright JD: Early metastatic spread after a complete response in locally advanced vulvar cancer treated with neoadjuvant chemoradiation: a case report. J Reprod Med; 2008 Sep;53(9):700-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early metastatic spread after a complete response in locally advanced vulvar cancer treated with neoadjuvant chemoradiation: a case report.
  • BACKGROUND: Preoperative chemoradiation for advanced vulvar cancer reduces the tumor size and decreases morbidity from operative resection.
  • CASE: A woman with locally advanced vulvar cancer had no evidence of metastatic disease at presentation.
  • She displayed complete resolution of her vulvar and groin disease but developed early metastatic spread to the lungs and bone.
  • CONCLUSION: Despite excellent local control, patients with locally advanced vulvar cancer are at risk for early metastatic spread.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Lung Neoplasms / secondary. Vulvar Neoplasms / drug therapy. Vulvar Neoplasms / radiotherapy
  • [MeSH-minor] Aged, 80 and over. Chemotherapy, Adjuvant. Fatal Outcome. Female. Humans. Neoadjuvant Therapy. Radiotherapy, Adjuvant. Remission Induction


14. Tsuji M, Nakai N, Ueda E, Takenaka H, Katoh N, Kishimoto S: Double cancer of plantar malignant melanoma and vulvar extramammary Paget's disease. J Dermatol; 2010 May;37(5):484-7
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double cancer of plantar malignant melanoma and vulvar extramammary Paget's disease.
  • A 75-year-old woman presented with a 2-year history of a pigmented nodular lesion on her left sole and a 9-year history of a red infiltrative plaque on the vulva.
  • Histopathological analysis of the vulvar lesion biopsy sample indicated extramammary Paget's disease (EMPD).
  • There was no evidence of metastasis in the computed tomography (CT) and (18)F-fluorodeoxyglucose positron emission tomography scans.
  • Melanoma cells were identified in the sentinel lymph nodes, and left radical lymph node dissection was performed after a course of neoadjuvant chemotherapy.
  • All the lymph nodes that were resected during the second operation tested negative for melanomas, and the plantar lesion was diagnosed as a stage IIIB malignant melanoma (pT4b, Na2, M0).
  • Thereafter, we administrated four courses of chemotherapy, and 8 months after the operation, there was no evidence of recurrence or metastatic lesions.
  • We present a case report of double cancer: a plantar malignant melanoma and vulvar EMPD, and also discuss the possible genetic mutations responsible for these two tumors.
  • [MeSH-major] Foot Diseases / pathology. Melanoma / pathology. Neoplasms, Multiple Primary / pathology. Paget Disease, Extramammary / pathology. Skin Neoplasms / pathology. Vulvar Neoplasms / pathology


15. Ferrandina G, Ranelletti FO, Lauriola L, Zannoni GF, Legge F, Gessi M, Salutari V, Scambia G: Cyclooxygenase-2 expression in lymph node metastasis of cervical and vulvar cancer. Oncol Rep; 2003 Nov-Dec;10(6):1799-804
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 expression in lymph node metastasis of cervical and vulvar cancer.
  • We investigated the expression of COX-2 in primary tumors and metastatic regional lymph nodes (TDL) from untreated and chemotherapy treated cervical cancer, as well as vulvar cancer.
  • Immunostaining of COX-2, expressed as values of COX-2 intensity density (COX-2 IDV) was performed on 57 metastatic TDL and 24 corresponding primary rumors from 14 cervical and 9 vulvar cancer patients admitted to the Department of Obstetrics and Gynecology, Catholic University of Rome.
  • In 6 locally advanced cervical cancer tissue samples, from both primary tumor and TDL, were obtained after chemotherapy treatment.
  • In untreated cervical cancer, COX-2 IDV in tumor cells from positive TDL were significantly lower (median 0.69, range 0.22-0.92) than those from primary tumors (median = 3.84, range 0.19-7.67) (p=0.011).
  • In cervical cancer exposed to chemotherapy, COX-2 IDV in tumor cells from positive TDL were significantly lower (median = 2.06, range 1.48-6.52) than those from primary tumors (median = 6.4, range 4.5-13.7) (p=0.037).
  • In vulvar cancer COX-2 IDV in tumor cells from positive TDL were lower (median = 0.39, range 0.02-6.09) than those from primary tumors (median = 2.49, range 0.71-8.10) (p=0.04).
  • In conclusion, we showed that COX-2 expression is down-regulated in cervical and vulvar tumor cells invading the regional lymph nodes with respect to primary tumors, thus emphasizing the need for deeper insight into the tissue specific relation between tumor cells and node microenvironment.
  • [MeSH-major] Isoenzymes / biosynthesis. Lymphatic Metastasis. Prostaglandin-Endoperoxide Synthases / biosynthesis. Uterine Cervical Neoplasms / enzymology. Vulvar Neoplasms / enzymology

  • Genetic Alliance. consumer health - Vulvar cancer.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14534699.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


16. Neto AG, Deavers MT, Silva EG, Malpica A: Metastatic tumors of the vulva: a clinicopathologic study of 66 cases. Am J Surg Pathol; 2003 Jun;27(6):799-804
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic tumors of the vulva: a clinicopathologic study of 66 cases.
  • Metastatic tumors involving the vulva are rare, with only a few series and case reports published in the English literature to date.
  • In this study, we present the clinicopathologic features of 66 cases of metastatic tumors of the vulva seen at the University of Texas M. D.
  • Anderson Cancer Center from 1944 to 2001.
  • The most common presentations were vulvar nodules or a mass (39 cases), pain (7 cases), and ulceration (5 cases).
  • Thirty percent of the patients received chemotherapy as treatment for the metastasis, 27% received radiotherapy, and the rest received some combination of chemotherapy, radiotherapy, and surgery.
  • Metastatic tumors of the vulva are rare; however, the diagnosis of these tumors is facilitated by the knowledge of a preexistent malignancy and the lack of a mucocutaneous intraepithelial lesion.
  • [MeSH-major] Vulvar Neoplasms / pathology. Vulvar Neoplasms / secondary
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12766584.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Sirotnak FM: Studies with ZD1839 in preclinical models. Semin Oncol; 2003 Feb;30(1 Suppl 1):12-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ZD1839 (Iressa; AstraZeneca Pharmaceuticals LP, Wilmington, DE) is an orally active, selective inhibitor of epidermal growth factor receptor-tyrosine kinase (EGFR-TK) that blocks signaling pathways responsible for driving proliferation, invasion, and survival of cancer cells.
  • In preclinical studies of cell lines and human tumor xenografts, ZD1839 as single-agent therapy produced growth inhibition in a wide variety of common solid tumor types including lung, prostate, breast, colon, and ovarian cancers.
  • The A431 vulvar carcinoma model, which expresses abnormally high levels of EGFR, was particularly sensitive to ZD1839 treatment, leading to tumor regression.
  • When ZD1839 was coadministered with cytotoxic chemotherapy agents or radiotherapy, additive or even synergistic antitumor activity was achieved.
  • The inhibition observed with ZD1839 treatment was not restricted to advanced metastatic tumors, but also extended to early lesions such as breast xenografts of human ductal carcinoma in situ.
  • The diverse and profound antitumor activities attained with ZD1839 treatment in tumor cells and in xenograft tumor models provided the rationale for clinical development of ZD1839.
  • [MeSH-minor] Animals. Drug Screening Assays, Antitumor. Humans. Tumor Cells, Cultured. Xenograft Model Antitumor Assays

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003, Elsevier Science (USA)
  • (PMID = 12644980.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA08748; United States / NCI NIH HHS / CA / CA56517
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Quinazolines; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  • [Number-of-references] 50
  •  go-up   go-down


18. Guirguis A, Kanbour-Shakir A, Kelley J: Epithelioid angiosarcoma of the mons after chemoradiation for vulvar cancer. Int J Gynecol Pathol; 2007 Jul;26(3):265-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid angiosarcoma of the mons after chemoradiation for vulvar cancer.
  • She was a 74-year-old woman who initially presented with stage II keratinizing squamous cell carcinoma of the vulva that underwent neoadjuvant chemoradiation followed by a radical vulvectomy with bilateral inguinal-femoral lymphadenectomy.
  • Our patient is the first case report of an angiosarcoma of the mons pubis after chemoradiation for vulvar cancer and the second reported angiosarcoma of the mons.
  • Time to presentation was approximately 4 years from the time of completion of chemoradiation.
  • She currently is undergoing systemic chemotherapy after being diagnosed with a metastatic pelvic lymph node.
  • As the treatment of vulvar cancer evolves, and more radiation therapy is given, the incidence of angiosarcomas will rise, requiring better diagnostic and treatment protocols.
  • [MeSH-major] Hemangiosarcoma / pathology. Vulvar Neoplasms / pathology
  • [MeSH-minor] Aged. Female. Humans. Immunohistochemistry. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy

  • Genetic Alliance. consumer health - Vulvar cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17581409.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Tanaka H, Umekawa T, Nagao K, Ishihara A, Toyoda N: Adenocarcinoma of mammary-like glands in the vulva successfully treated by weekly paclitaxel. Int J Gynecol Cancer; 2005 May-Jun;15(3):568-71
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of mammary-like glands in the vulva successfully treated by weekly paclitaxel.
  • Histologic examination showed the same morphologic findings as scirrhus type of primary breast carcinoma.
  • This disease was diagnosed as an adenocarcinoma arising in mammary-like glands of the vulva.
  • Bone scan showed multiple foci in the sternum, costa, and vertebrae, consistent with metastatic disease.
  • We administered five courses of weekly paclitaxel chemotherapy, which achieved a partial response.
  • In our case, the fine-needle aspiration cytology was a rapid and minimally invasive method of diagnosis, and the findings were extremely similar to those of the scirrhus type of primary breast carcinoma.
  • Weekly paclitaxel chemotherapy may be one of the safe and effective treatments for this disease with distant metastases, even in extremely aged patients (over 80 years).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / therapeutic use. Paclitaxel / therapeutic use. Vulvar Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882189.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


20. Blake P: Radiotherapy and chemoradiotherapy for carcinoma of the vulva. Best Pract Res Clin Obstet Gynaecol; 2003 Aug;17(4):649-61
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy and chemoradiotherapy for carcinoma of the vulva.
  • Radiotherapy may be used in the treatment of vulval cancer as an alternative to surgery in unfit patients, as an adjuvant to surgery in patients with poor prognosis tumours and for the treatment of inoperable, recurrent and metastatic disease.
  • This chapter presents the historical development of radiotherapy for vulval cancer, the role of radiotherapy in the treatment of the primary tumour and also the loco-regional nodes, both for prophylaxis and for proven node metastasis.
  • Techniques for delivering radiotherapy are then discussed and are followed by protocols detailing radiotherapy and chemotherapy doses for different clinical situations.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Vulvar Neoplasms / drug therapy. Vulvar Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Brachytherapy. Chemotherapy, Adjuvant. Female. Humans. Inguinal Canal. Lymphatic Metastasis. Neoadjuvant Therapy. Radiotherapy, High-Energy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12965137.001).
  • [ISSN] 1521-6934
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 25
  •  go-up   go-down


21. Vázquez JP, Cobo SL, Antón FM, Asado AC, Vidart JA, Coronado P, Díaz-Rubio E: Brain metastasis and carcinomatous meningitis from vulvar squamous cell carcinoma: case report. Eur J Gynaecol Oncol; 2007;28(2):152-4
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastasis and carcinomatous meningitis from vulvar squamous cell carcinoma: case report.
  • BACKGROUND: Brain metastasis and carcinomatous meningitis from gynecological tumors are an uncommon event, usually related to choriocarcinoma, ovarian and cervical cancer.
  • CASE: A 74-year-old woman was diagnosed with locally advanced vulvar squamous carcinoma.
  • Initial therapy consisted of multiagent chemotherapy and vulvar, pelvis and groin irradiation.
  • The patient subsequently developed widely spread metastatic disease including brain and meningeal metastases.
  • CONCLUSION: The rising incidence of central nervous system metastasis in the last two decades is probably associated with treatment-related improvement in life expectancy.
  • To our knowledge, this is the first case reported of brain metastases and meningeal carcinomatosis associated with vulvar squamous cell carcinoma.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Squamous Cell / secondary. Meningeal Neoplasms / secondary. Vulvar Neoplasms / pathology
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17479684.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


22. Montana GS, Thomas GM, Moore DH, Saxer A, Mangan CE, Lentz SS, Averette HE: Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study. Int J Radiat Oncol Biol Phys; 2000 Nov 1;48(4):1007-13
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study.
  • PURPOSE: To determine if patients with carcinoma of the vulva, with N2/N3 lymph nodes, could undergo resection of the lymph nodes and primary tumor following preoperative chemo-radiation.
  • Patients underwent a split course of radiation, 4760 cGy to the primary and lymph nodes, with concurrent chemotherapy, cisplatin/5-FU, followed by surgery.
  • RESULTS: Four patients did not complete the chemo-radiation, because three expired and one refused to complete the treatment.
  • Four patients who completed chemo-radiation did not undergo surgery, because two of them died of non-cancer-related causes, and in the other two patients, the nodes remained unresectable.
  • Nineteen patients developed recurrent and/or metastatic disease.
  • Two patients died of treatment-related complications.
  • CONCLUSION: High resectability and local control rates of the lymph nodes were obtained in patients with carcinoma of the vulva with N2/N3 nodes treated preoperatively with chemo-radiation.
  • [MeSH-major] Carcinoma / drug therapy. Carcinoma / radiotherapy. Lymph Node Excision. Vulvar Neoplasms / drug therapy. Vulvar Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Groin. Humans. Lymphatic Metastasis / pathology. Middle Aged. Neoplasm Staging. Treatment Failure

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11072157.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 37517; United States / NCI NIH HHS / CA / CA27469
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Husain A, Akhurst T, Larson S, Alektiar K, Barakat RR, Chi DS: A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration. Gynecol Oncol; 2007 Jul;106(1):177-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration.
  • PURPOSE: To determine the accuracy of (18)FDG PET in identifying sites of metastatic disease prior to pelvic exenteration or radical resection in patients (pts) with recurrent cervical or vaginal cancers.
  • METHODS: Pts with recurrent cervical or vaginal cancer being evaluated for surgical resection were enrolled in a prospective study approved by the institutional human subjects review board.
  • All pts had undergone prior pelvic radiation therapy and five patients had also received chemotherapy.
  • CT/MRI scans identified three patients with possible metastatic disease in the following sites:.
  • After surgical and pathological evaluation, only one of these sites, the lungs, was confirmed to have metastatic disease.
  • PET scans identified possible metastatic disease in nine patients and included the following sites:.
  • After surgical and pathologic evaluation metastatic disease was identified in five of these pts at the following sites: iliac nodes, 2; para-aortic nodes, 1; bowel wall, 1; and lungs, 1.
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radionuclide imaging. Neoplasm Recurrence, Local / surgery. Pelvic Exenteration. Positron-Emission Tomography / methods. Positron-Emission Tomography / standards. Prospective Studies. Tomography, X-Ray Computed. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / radionuclide imaging. Uterine Cervical Neoplasms / surgery. Vaginal Neoplasms / pathology. Vaginal Neoplasms / radionuclide imaging. Vaginal Neoplasms / surgery. Vulvar Neoplasms / pathology. Vulvar Neoplasms / radionuclide imaging. Vulvar Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17477959.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


24. Piura B, Rabinovich A, Huleihel M: [Matrix metalloproteinases and their tissue inhibitors in malignancies of the female genital tract]. Harefuah; 2003 Nov;142(11):786-91, 804

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Matrix metalloproteinases and their tissue inhibitors in malignancies of the female genital tract].
  • Their proteolytic activity depends on their binding to metal Zinc and is controlled by tissue inhibitors of MMP (TIMPs).
  • Degradation of the extracellular matrix and basement membrane is an important component of the process of tumor invasiveness, progression, angiogenesis and metastatic spread.
  • Since MMPs may serve as markers of tumor behavior and as predictors of survival and since synthetic inhibitors of MMP may have a place in the treatment of cancer, researching MMPs and their tissue inhibitors in malignant diseases has attracted growing attention.
  • Studies on MMPs and their tissue inhibitors in malignancies of the female genital tract have shown the following:.
  • 1) In ovarian carcinoma and cervical carcinoma, over-expression of MMP-2 and MMP-9 is associated with invasiveness, metastatic spread and poor prognosis;.
  • 2) In endometrial carcinoma, MMP-7 (matrilysin) is the main MMP associated with invasiveness, metastatic spread and poor prognosis;.
  • In vulvar squamous cell carcinoma, over-expression of MMP-13 is associated with invasiveness, metastatic spread and poor prognosis.
  • It is speculated that using synthetic drugs that inhibit MMPs in combination with conventional chemotherapy may contribute to the improvement of treatment results in cancer patients.
  • [MeSH-major] Genital Neoplasms, Female / enzymology. Genital Neoplasms, Female / pathology. Matrix Metalloproteinases / metabolism. Tissue Inhibitor of Metalloproteinases / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14631913.001).
  • [ISSN] 0017-7768
  • [Journal-full-title] Harefuah
  • [ISO-abbreviation] Harefuah
  • [Language] heb
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Israel
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tissue Inhibitor of Metalloproteinases; EC 3.4.24.- / Matrix Metalloproteinases
  • [Number-of-references] 32
  •  go-up   go-down


25. Noronha V, Cooper DL, Higgins SA, Murren JR, Kluger HM: Metastatic myoepithelial carcinoma of the vulva treated with carboplatin and paclitaxel. Lancet Oncol; 2006 Mar;7(3):270-1
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic myoepithelial carcinoma of the vulva treated with carboplatin and paclitaxel.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Myoepithelioma / drug therapy. Vulvar Neoplasms / drug therapy
  • [MeSH-minor] Adult. Carboplatin / administration & dosage. Female. Humans. Lymphatic Metastasis. Paclitaxel / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Myoepithelial carcinoma.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16510337.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down






Advertisement